MX2019001125A - Inhibidores de cinasa macrociclica. - Google Patents
Inhibidores de cinasa macrociclica.Info
- Publication number
- MX2019001125A MX2019001125A MX2019001125A MX2019001125A MX2019001125A MX 2019001125 A MX2019001125 A MX 2019001125A MX 2019001125 A MX2019001125 A MX 2019001125A MX 2019001125 A MX2019001125 A MX 2019001125A MX 2019001125 A MX2019001125 A MX 2019001125A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- macrocycle
- same
- present disclosure
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención se refiere a ciertos inhibidores de cinasa macrocíclica, composiciones farmacéuticas que contienen los mismos, y métodos para usar el mismo para tratar la enfermedad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662367886P | 2016-07-28 | 2016-07-28 | |
PCT/US2017/044214 WO2018022911A1 (en) | 2016-07-28 | 2017-07-27 | Macrocycle kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019001125A true MX2019001125A (es) | 2019-06-12 |
Family
ID=61016718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019001125A MX2019001125A (es) | 2016-07-28 | 2017-07-27 | Inhibidores de cinasa macrociclica. |
Country Status (15)
Country | Link |
---|---|
US (1) | US10689400B2 (es) |
EP (1) | EP3490564A4 (es) |
JP (1) | JP2019527230A (es) |
KR (1) | KR20190034225A (es) |
CN (1) | CN109715165A (es) |
AU (1) | AU2017302019A1 (es) |
BR (1) | BR112019001607A2 (es) |
CA (1) | CA3031100A1 (es) |
IL (1) | IL264395A (es) |
MX (1) | MX2019001125A (es) |
RU (1) | RU2019105587A (es) |
SG (1) | SG11201900163PA (es) |
TW (1) | TW201815799A (es) |
WO (1) | WO2018022911A1 (es) |
ZA (1) | ZA201901034B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA031863B1 (ru) | 2014-01-24 | 2019-03-29 | ТиПи ТЕРАПЬЮТИКС, ИНК. | Диарильные макроциклы в качестве модуляторов протеинкиназ |
US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
EP3325488B1 (en) | 2015-07-21 | 2020-06-24 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Tp生物醫藥公司 | 巨環激酶抑制劑 |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
BR112020001695A2 (pt) * | 2017-07-28 | 2020-07-21 | Turning Point Therapeutics, Inc. | compostos macrocíclicos e usos dos mesmos |
CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
RS63787B1 (sr) | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
EP3774812A4 (en) | 2018-03-28 | 2021-12-15 | Fochon Pharmaceuticals, Ltd. | MACROCYCLIC COMPOUNDS AS TRK CINEMA INHIBITORS |
CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
CA3117200A1 (en) | 2018-10-22 | 2020-04-30 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
CN113727984B (zh) * | 2019-05-21 | 2024-03-15 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
CN112110938B (zh) * | 2019-06-21 | 2021-11-09 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
EP4114530A4 (en) * | 2020-03-02 | 2024-04-17 | Turning Point Therapeutics Inc | THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS |
CN113754682B (zh) * | 2020-06-04 | 2023-01-06 | 赛诺哈勃药业(成都)有限公司 | 具有大环结构的化合物及其用途 |
WO2022171139A1 (zh) * | 2021-02-10 | 2022-08-18 | 北京国鸿生物医药科技有限公司 | 一种巨环化合物、药物组合物以及其用途 |
CN113354548A (zh) * | 2021-04-12 | 2021-09-07 | 常熟耐素生物材料科技有限公司 | 一种基于六亚甲基四胺的植物多烯酚醛胺环氧固化剂及其制备方法 |
WO2023078267A1 (zh) * | 2021-11-02 | 2023-05-11 | 赛诺哈勃药业(成都)有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3298885B2 (ja) | 1993-03-25 | 2002-07-08 | ファルマシア・アンド・アップジョン・カンパニー | ドーパミン作働性活性を有するインドールテトラリン類 |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
EA201100450A1 (ru) | 2008-09-08 | 2011-10-31 | Мерк Патент Гмбх | Макроциклические пирамидины в качестве ингибиторов протеинкиназы |
CA2952692C (en) | 2008-09-22 | 2020-04-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds |
TWI458729B (zh) | 2008-10-22 | 2014-11-01 | Array Biopharma Inc | 作為TRK激酶抑制劑之經取代吡唑并〔1,5-a〕嘧啶化合物 |
EP2962566A1 (en) | 2008-10-31 | 2016-01-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
CR20170098A (es) | 2010-05-20 | 2017-07-17 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de quinasa trk |
US8757434B2 (en) * | 2010-07-01 | 2014-06-24 | The Coca-Cola Company | Merchandiser |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
RU2598840C2 (ru) * | 2011-05-19 | 2016-09-27 | Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii | Новые соединения |
WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
RU2014110399A (ru) | 2011-08-19 | 2015-09-27 | Мерк Шарп И Доум Корп. | Кристаллические формы вгс протеазного ингибитора |
KR20140095477A (ko) * | 2011-09-30 | 2014-08-01 | 입센 파마 에스.에이.에스 | 마크로시클릭 lrrk2 키나제 억제제 |
BR112014007622A2 (pt) | 2011-09-30 | 2017-04-04 | Oncodesign Sa | inibidores de flt3 cinase macrocíclicos |
NZ627900A (en) | 2012-03-06 | 2016-08-26 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
EP2822559B1 (en) | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
CA2866143C (en) | 2012-03-09 | 2020-08-04 | Lexicon Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
KR20150133765A (ko) * | 2013-03-15 | 2015-11-30 | 온코디자인 에스.에이. | 거대고리 rip2 키나제 억제제 |
CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
EA031863B1 (ru) * | 2014-01-24 | 2019-03-29 | ТиПи ТЕРАПЬЮТИКС, ИНК. | Диарильные макроциклы в качестве модуляторов протеинкиназ |
US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
JP6917974B2 (ja) | 2015-07-06 | 2021-08-11 | ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. | ジアリール大環状多形 |
EP3325488B1 (en) | 2015-07-21 | 2020-06-24 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Tp生物醫藥公司 | 巨環激酶抑制劑 |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
BR112020001695A2 (pt) | 2017-07-28 | 2020-07-21 | Turning Point Therapeutics, Inc. | compostos macrocíclicos e usos dos mesmos |
-
2017
- 2017-07-27 TW TW106125249A patent/TW201815799A/zh unknown
- 2017-07-27 CN CN201780056515.5A patent/CN109715165A/zh active Pending
- 2017-07-27 US US16/320,589 patent/US10689400B2/en active Active
- 2017-07-27 KR KR1020197003927A patent/KR20190034225A/ko not_active Application Discontinuation
- 2017-07-27 RU RU2019105587A patent/RU2019105587A/ru not_active Application Discontinuation
- 2017-07-27 EP EP17835284.5A patent/EP3490564A4/en active Pending
- 2017-07-27 BR BR112019001607-4A patent/BR112019001607A2/pt not_active Application Discontinuation
- 2017-07-27 AU AU2017302019A patent/AU2017302019A1/en not_active Abandoned
- 2017-07-27 MX MX2019001125A patent/MX2019001125A/es unknown
- 2017-07-27 JP JP2019504675A patent/JP2019527230A/ja active Pending
- 2017-07-27 WO PCT/US2017/044214 patent/WO2018022911A1/en unknown
- 2017-07-27 SG SG11201900163PA patent/SG11201900163PA/en unknown
- 2017-07-27 CA CA3031100A patent/CA3031100A1/en active Pending
-
2019
- 2019-01-22 IL IL264395A patent/IL264395A/en unknown
- 2019-02-18 ZA ZA2019/01034A patent/ZA201901034B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112019001607A2 (pt) | 2019-04-30 |
RU2019105587A3 (es) | 2020-11-18 |
AU2017302019A1 (en) | 2019-02-07 |
SG11201900163PA (en) | 2019-02-27 |
ZA201901034B (en) | 2021-06-30 |
WO2018022911A1 (en) | 2018-02-01 |
EP3490564A1 (en) | 2019-06-05 |
KR20190034225A (ko) | 2019-04-01 |
JP2019527230A (ja) | 2019-09-26 |
US20190169208A1 (en) | 2019-06-06 |
RU2019105587A (ru) | 2020-08-28 |
US10689400B2 (en) | 2020-06-23 |
EP3490564A4 (en) | 2020-02-26 |
CA3031100A1 (en) | 2018-02-01 |
IL264395A (en) | 2019-02-28 |
TW201815799A (zh) | 2018-05-01 |
CN109715165A (zh) | 2019-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
PH12020500033A1 (en) | Macrocyclic compounds and uses thereof | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
CA2956871C (en) | Compounds active towards bromodomains | |
PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
TR201909887T4 (tr) | ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri. | |
PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
PH12015502698A1 (en) | Dual selective pi3 delta and gamma kinase inhibitors | |
MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
MX2020010116A (es) | Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). | |
MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
WO2016073771A3 (en) | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
MX2017012342A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades,. | |
MX2018013573A (es) | Ciertos inhibidores de la proteína cinasa. |